Toggle menu

RAMPP trial

Start date:
2017
End date:
March 2019
Co-ordinated by:
Bernadette Gallagher
Main trial site:
RIE

The RAMPP study aims to investigate the use of a pleural vent (rocket) versus standard care in patients with Primary Spontaneous Pnuemothorax in a randomised controlled trial.

Eligibility Criteria

Inclusion criteria:
1. Presenting with primary spontaneous pneumothorax as confirmed by a chest radiograph or a CT scan.
2. Age >= 18 years old and <= 55 years old.
3. Ability to consent to participation.

Exclusion Criteria
1. Known or suspected underlying lung disease (including >20 pack year smoking history).
2. Evidence of tension pneumothorax (these patients should be treated immediately as medical emergencies).
3. Females who are pregnant or lactating.
4. Inability to consent or comply with the trial requirements.
5. Contraindication to thoracic procedure. (Only applies to patients being enrolled into Intervention or Control arms – i.e. not observational cohort).
6. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant’s ability to participate in the trial.

 

Funding:  Medical Research Council and the National Institute for Health Research (UK).

Sponsor:  University of Oxford, Churchill Hospital (UK)

Setting: This is a multi-centre study being co-ordinated from Oxford.

 

 

Local PI

Dr Marie-Clare Harris

Consultant in Emergency Medicine

Research Team

Bernadette Gallagher

Senior Research Nurse

Allan MacRaild

Stroke Lead Research Nurse

More EMERGE Trials

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

Read more

ATTEST2 Trial

Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis (ATTEST 2)

People who develop an Acute Kidney Injury (AKI) often have a poor prognosis and many go on to develop chronic kidney disease (CKD). The recognition that AKI and CKD are linked is recent and the molecular pathways that control the transition from acute injury to chronic disease are not well defined. Currently there are no specific treatments that reduce the risk of progressing to CKD after AKI.

Preliminary investigations (not yet published) suggest that AKI causes sustained activation of the endothelin (ET) system to the long-term detriment of renal and systemic haemodynamic function. These pilot data form the basis of our project that seeks to determine whether the ET system is active in patients with AKI and, thus, represents a potential target for therapeutic intervention.

KRAKIL aims to recruit altogether 100 patients from across the emergency department, acute medical unit and inpatient wards at the Royal Infirmary. 50 of which with AKI’s and 50 matched controls with normal kidney function. We will monitor their bloods and urine for 90 days and compare the data from between the two groups.

Read more

KRAKIL Study